# Haploporic acid B and C, New Antibacterial Sesquiterpenoids from the Basidiomycete *Haploporus odorus*

MORITA Yasufumi<sup>\*</sup> MURANAKA Hideaki<sup>\*\*</sup> SHIBATA Hisao<sup>\*\*\*</sup>

Two new dimeric drimane sesquiterpenoid ethers, haploporic acid B (2) and C (3), were isolated from the fruit-bodies of fungus *Haploporus odorus*, together with two known sesquiterpenoid dimmers (1 and 4). These structures were determined by spectroscopic and chemical methods. Haploporic acid B (2) showed strong antibacterial activity against *Staphylococcus aureus*. **Keywords** : Haploporic acid, Drimane sesquiterpenoid, Unsymmetrical dimer, Basidiomycete, *Haploporus odorus*, Antibacterial activity

### 1. Introduction

In the course of our investigation on chemical components from Basidiomycetes, we have reported the chemotaxonomy of Russulaceae and Boletaceae fungi<sup>1-5)</sup>, some biologically active compounds from Aphyllophorales fungi.<sup>6-9)</sup> Haploporus odorus (Ezoshiroamitake in Japanese, Polyporaceae) is a white-rotting fungus growing mainly on a willow tree, rarely on a cherry tree, in a cold district. Its fruit-body is a white-pale yellow semicircle having a sweet smell like an anise. We have reported the isolation and structural determination of a novel symmetrical dimeric drimane sesquiterpenoid ether of isocitric acid, haploporic acid A (1) form the fruit-bodies of H. odorus.<sup>8)</sup> Further investigation of this fungus, we have been found that the extract of H. odorus had the antibacterial activity against gram-positive bacteria. In this paper, we wish to report the isolation and structural determination of the antibacterial compounds from this fungus.

# 2. Materials and Methods

The dried fruit-bodies of *H. odorus* (110g) were extracted with dichloromethane, and its extract showed antibacterial activity against *Staphylococcus aureus*. The extract was purified with  $SiO_2$ , ODS, and recrystallized to afford compounds 1-4. The yield of compounds 1-4 were 714.7, 34.6, 28.9, and 419.4 mg, respectively.

<sup>\*</sup>一般教養科

<sup>\*\*</sup>物質工学科(現·物質化学工学科)

<sup>\*\*\*</sup>信州大学農学部応用生命科学科

#### 3. Results and Discussion

Compound **2** (haploporic acid B) was isolated as a colorless oil and the FAB (positive)-MS showed  $[M + Na]^+$  at m/z 871,  $[M-H+2Na]^+$  at m/z 893, indicating that the molecular weight of **2** is 848. The IR spectrum showed the absorptions of carboxylic acid (3500-2600 and 1715cm<sup>-1</sup>), ester carbonyl (1740cm<sup>-1</sup>), and olefine (1640cm<sup>-1</sup>). In the <sup>1</sup>H-NMR spectrum for **2**, four olefinic proton signals due to two exomethylene  $[\delta_H 4.93(1H, d, J=1.8Hz), \delta_H 4.87(1H, d, J=1.2Hz), \delta_H 4.79(1H, d, J=1.8Hz), \delta_H 4.77(1H, d, J=1.2Hz)]$ , three methoxyl ( $\delta_H$  3.78, 3.69, 3.68, each 3H, *s*) and four *tert*-methyl ( $\delta_H$  0.80, 0.76, 0.75, 0.73, each 3H, *s*) groups.

The proton signals due to isocitrate and drimane sesquiterpene moieties were also observed in the <sup>1</sup>H-NMR spectrum for 2, which were supported by <sup>1</sup>H-<sup>1</sup>H COSY and HMBC. The <sup>13</sup>C-NMR spectrum showed 45 carbon signals. The analysis of DEPT and HMQC spectrum suggested it to be as follows ; *tert*-CH<sub>3</sub> x 4, CH<sub>2</sub> x 12, CH x 6, C x 4, OCH<sub>3</sub> x 3, OCH<sub>2</sub> x 4, OCH x 2, >C=CH<sub>2</sub> x 2, COO x 4, COOH x 2, OH x 1. These results suggested that the molecular formula for 2 was  $C_{45}H_{68}O_{15}$ . The general details of the <sup>1</sup>H- and <sup>13</sup>C-NMR spectrum were very similar to those of 4 which has been reported from the fungus Haploporus odorus<sup>8)</sup> and Cryptoporus volvatus<sup>10)</sup>, although small differences were observed. On the other hand, the molecular weight clarified by FAB-MS data and the molecular formula of 2 agreed with those of 4. Thus, 2 was suggested to be the isomer of 4. Finally, further interpretation of HMBC spectrum of 2 clarified that the location of dimerization was at C-4' and C-15'', in which the long range couplings were observed between H-15'' ( $\delta_{\rm H}$  3.87, 3.64) and C-4' ( $\delta_{\rm C}$ 170.0), showing in Fig. 1. The absolute stereochemistry of 2 was confirmed by chemical transformation. Methylation with diazomethane, reduction with LAH and acetylation of 2 afforded to **6** showing in Fig. 2. The spectral data of **6** were identical to those of the tetraacetate prepd. from 1 in same methods. Therefore, the structure of 2 including the absolute configuration was determined as 2showing in Fig. 1.

Compound 3 (haploporic acid C) was isolated as a colorless oil. It showed very similar IR absorption to that of 2. The <sup>1</sup>H- and <sup>13</sup>C-NMR data for 3 were also similar to those of 2 (see Table 1 and 2), except for one methoxyl proton signal ( $\delta_{\rm H}$  3.72, 3H, *s*,  $\delta_{\rm C}$  52.6). On the other hand, the HMBC analysis revealed that the location of dimerization were at C-4' ( $\delta_{\rm C}$  170.2) and C-15'' ( $\delta_{\rm H}$  3.89, 3.69,  $\delta_{\rm C}$  70.5), C-4''' ( $\delta_{\rm C}$  169.7) and C-15 ( $\delta_{\rm H}$  4.47, 3.24,  $\delta_{\rm C}$  71.1) like as 1. Thus, 3 was suggested to be demethyl compound of 1, which was supported by the FAB-MS data (*m/z* 825 [M + Na]<sup>+</sup>). Methylation of 3 with diazomethane afforded to 3-trimethyl, whose analytical data were identical to those of 5 prepd. from 1 in same method. Therefore, the structure of 3 including the absolute configuration was determined as 3 showing in Fig. 1.

Compound 1 (colorless powder, mp 203-204°C,  $[\alpha]_D$  +30.0°) and 4 (colorless oil,  $[\alpha]_D$  +47.0°) were identified with haploporic acid A and cryptoporic acid E, respectively, by directly comparing their spectral data with those of authentic samples.<sup>7, 10</sup>)

# Antibacterial Sesquiterpenoids from H. odorus

Table 1. 'H-NMR Data for Compounds 1-3 and 5"	Table 1.	<sup>1</sup> H-NMR	Data for	Compounds	1-3	and	<b>5</b> #,\$
-----------------------------------------------	----------	--------------------	----------	-----------	-----	-----	---------------

pos	ition	1	2	3	5
1	а	1.00. ddd (12.4, 12.4, 3.2*)	1.13. <i>m</i>	1.35. <i>m</i>	1.26. <i>m</i>
	b	1.72, br <i>d</i> (12.4)	1.66, br <i>d</i> (13.2)	1.70, <i>m</i>	1.79, br <i>d</i> (12.6)
2	а	1.45, <i>m</i>	1.55, <i>m</i>	1.54, <i>m</i>	1.50, <i>m</i>
	b	1.55, <i>m</i>	1.55, <i>m</i>	1.60, <i>m</i>	1.60, <i>m</i>
3	а	1.15, ddd (13.2, 13.2, 3.6)	1.25, <i>m</i>	1.25, <i>m</i>	1.23, <i>m</i>
	b	1.45, <i>m</i>	1.45, <i>m</i>	1.63, <i>m</i>	1.60, <i>m</i>
5		1.45, <i>m</i>	1.47, dd (12.6, 2.4)	1.26, <i>m</i>	1.72, dd (12.6, 2.4)
6	а	1.32, <i>m</i>	1.34, <i>m</i>	1.30, <i>m</i>	1.31, ddd (13.2, 13.2 4.2)
	b	1.67, <i>m</i>	1.59, <i>m</i>	1.50, <i>m</i>	1.50, <i>m</i>
7	а	2.05, <i>m</i>	2.09, ddd (12.6, 12.6, 4.8)	1.86, <i>m</i>	1.88, ddd (13.2, 13.2 5.4)
	b	2.46, br <i>d</i> (13.6)	2.40, <i>m</i>	2.31, br d (15.1)	2.24, br <i>d</i> (13.2)
9		1.94, br <i>d</i> (10.8)	2.01, br <i>d</i> (7.8)	2.13, <i>m</i>	2.32, br <i>d</i> (6.0)
11	а	3.89, dd (12.8, 1.2)	3.60, dd (10.2, 3.0)	3.69, <i>m</i>	3.62, <i>dd</i> (9.6, 3.6)
	b	3.98, dd (12.8, 11.2)	3.99, dd (10.2, 9.0)	4.08, dd (9.5, 9.5)	3.82, <i>dd</i> (9.6, 9.6)
12	а	4.84, br <i>s</i>	4.77, <i>d</i> (1.2)	4.55, <i>s</i>	4.29, <i>s</i>
	b	5.01, br <i>s</i>	4.87, <i>d</i> (1.2)	4.84, <i>s</i>	4.75, <i>s</i>
13		0.74, <i>s</i>	0.76, <i>s</i>	0.76, <i>s</i>	0.80, <i>s</i>
14		0.79, <i>s</i>	0.75, <i>s</i>	0.79, <i>s</i>	0.82, <i>s</i>
15	а	3.55, <i>d</i> (11.2)	3.09, <i>d</i> (11.4)	3.24, <i>d</i> (11.2)	3.60, <i>d</i> (11.4)
	b	4.45, d (11.2)	3.43, <i>d</i> (11.4)	4.47, <i>d</i> (11.2)	3.88, <i>d</i> (11.4)
1'		4.05, d (2.0)	4.08, <i>d</i> (5.4)	4.47, <i>d</i> (7.1)	4.18, <i>d</i> (5.4)
2'		3.49, <i>ddd</i> (11.2, 3.2, 2.0)	3.38, <i>ddd</i> (7.2, 6.0, 5.4)	3.42, ddd (7.8, 7.1, 6.1)	3.45, <i>ddd</i> (9.6, 5.4, 4.2)
3'	а	2.77, <i>dd</i> (16.4, 3.2)	2.71, <i>dd</i> (16.2, 7.2)	2.67, <i>dd</i> (17.3, 6.1)	2.58, <i>dd</i> (16.8, 4.2)
	b	2.92, <i>dd</i> (16.4, 11.2)	2.91, <i>dd</i> (16.2, 6.0)	2.80, <i>dd</i> (17.3, 7.8)	2.80, <i>dd</i> (16.8, 9.6)
1"	а		1.13, <i>m</i>	1.22 m	
	b		1.71, br <i>d</i> (12.6)	1.70 <i>m</i>	
2"	а		1.55, <i>m</i>	1.54 m	
	b		1.55, <i>m</i>	1.60 <i>m</i>	
3"	a		1.25, <i>m</i>	1.25 m	
	b		1.45, <i>m</i>	1.50 m	
5"			1.44, <i>dd</i> (12.6, 2.4)	1.26 m	
6"	a		1.34, <i>m</i>	1.30 m	
	b		1.59, m	1.68 m	
7	a		1.95, <i>ddd</i> (12.6, 12.6, 4.2)	1.86 m	
0"	b		2.36, m	2.26, br $d$ (16.3)	
9 <sup></sup>			1.80, br $a$ (8.4)	2.10 m	
11	a L		3.67, ad(10.2, 3.0)	3.69 m	
1.2"	0		3.93, t (10.2)	5.75 m 4.90 a	
12	a h		4.79, a (1.8)	4.89, S	
12"	U		4.93, u (1.8)	4.70, s	
1.4"			0.73, 3	0.72, s	
15"	а		3.64 d(11.2)	3.68 d(10.9)	
15	u h		3.97 d(11.2)	3.89 d(10.9)	
1'''	0		4.29 d (4.2)	4 30.  br s	
2'''			3.51. ddd (10.2, 4.2, 3.6)	3.68. m	
3""	а		2.80, <i>dd</i> (17.4, 10.2)	2.64, dd (16.6, 4.6)	
-	b		2.88, <i>dd</i> (17.4, 3.6)	2.96, <i>dd</i> (16.6, 8.8)	
OM	Ie	3.68, <i>s</i>	3.68, <i>s</i>	3.72, <i>s</i>	3.71, <i>s</i>
			3.69, <i>s</i>	·	3.71, <i>s</i>
			3.78. 5		

# Recorded at 500MHz in CDCl<sub>3</sub>.

 $\$  Signals were assigned by COSY, HMQC and HMBC.

\* *J*(Hz)

Table 2.	<sup>13</sup> C-NMR Data for Compounds 1-3 and			
position	1	2	3	5
1	39.3	38.3	38.5	39.4
2	18.8	18.6	18.5	18.5
3	36.6	35.2	35.4	35.6
4	38.8	37.4	38.5	37.3
5	47.8	47.8	46.4	46.7
6	23.0	23.4	23.2	23.3
7	36.4	37.1	36.9	36.9
8	145.4	146.4	146.8	147.7
9	51.9	54.9	56.7	55.4
10	37.9	38.4	37.3	39.7
11	64.0	68.0	69.6	70.7
12	109.3	108.2	107.9	107.4
13	15.9	15.8	15.6	14.8
14	17.4	17.7	17.6	17.9
15	69.7	71.8	71.1	71.3
1'	73.0	77.8	77.2	79.5
2'	44.4	44.6	43.5	44.1
3'	32.5	33.1	31.5	31.8
4'	169.3	170.0	170.2	170.6
5'	170.1	171.1	171.9	171.4
6'	179.7	178.0	176.7	172.0
1"		38.8	38.6	
2"		18.4	18.5	
3"		35.8	35.5	
4"		37.9	38.8	
5		47.2	46.4	
6" 7"		23.2	23.4	
/" 0"		37.0	37.1	
8" 0"		145.7	147.8	
9		54.5 29.4	54.1	
10		58.4 67.4	57.7 68 5	
11		102.9	107.2	
12		108.8	107.5	
13		17.8	17.8	
14		70.0	70.5	
15		76.8	70.5	
1 2'''		/0.8 /3.6	79. <del>4</del> 11.6	
2 3'''		45.0 31.4	32.2	
5 4'''		171.5	169.7	
		170.9	173.0	
5 6'''		178.4	176.2	
OMe	52 3	52.3	52.6	52.0
01110	-	52.3	-	52.3
	-	52.4	-	-









Arrows show the diagnostically significant C-H correlation found by HMBC.

# Recorded at 125Hz in CDCl<sub>3</sub>

<sup>\$</sup> Signals were assigned by DEPT, HMQC and HMBC.



Fig. 2. Chemical transformation to a related compound 6.

bacteria	concentration <sup>#</sup> (µg/disk)				
compounds	B. subtilis	S. aureus	P. fluorescens	E. coli	
<b>1</b> (haploporic acid A)	50	6.25	NA <sup>\$</sup>	NA	
<b>2</b> (haploporic acid B)	25	1.56	NA	NA	
<b>3</b> (haploporic acid C)	50	6.25	NA	NA	
4 (cryptoporic acid E)	100	100	NA	NA	

Table 3. Minimum Inhibitory Concentration of compounds 1-4 on Bacteria (MIC)

#: Samples were tested at 200, 100, 50, 25, 12.5, 6.25, 3.12, 1.56, 0.78 and 0.39 µg/disk by the paper disk method. The minimum concentrations necessary to cause a clear inhibition zone over 8mm are listed.

: NA; no activity at the highest does tested (200  $\mu$ g/disk).

Antibacterial activity of dimeric drimane sesquiterpenes of isocitric acid (1-4) were measured by the paper disc method. The results are summarized in Table 3. Compound 2 (haploporic acid B) showed strong antibacterial activity, 1 (haploporic acid A) and 3 (haploporic acid C) showed moderate activity, and 4 (cryptoporic acid E) showed weak activity against two gram-positive bacteria. However, all compounds indicated no activity against two gram-negative bacteria. The activity-enhancing effect of these compounds on antibacterial activity was suggested to the location of dimerization, because the unsymmetrical dimer 2 esterizing at C-4' and C-15'' was higher activity than 4 esterizing at C-5' and C-15''.

## 4. Experimental

*Instruments*. NMR spectra (TMS as the internal standard) were obtained with a Bruker AC500 instrument, and IR spectra were recorded on a Jasco FT/IR-8000 spectrometer. MS spectra were measured with JEOL AX-500. The optical rotation was measured with a Jasco DIP-1000.

*Extraction and Isolation of compounds* 1-4. The dried fruiting bodies (110g) of *H. odorus* collected in Nagano prefecture, Japan, were extracted with methylene chloride (100ml) to afford a pale yellow paste (18g), which showed antibacterial activity (the minimum inhibitory concentration =  $100\mu g$  per disc) against *Staphylococcus aureus*, The extract was chromatographed on silica gel, eluting with CHCl<sub>3</sub>, CHCl<sub>3</sub>-MeOH (20:1), (10:1), (5:1), (1:1), and MeOH, in that order. A CHCl<sub>3</sub>-MeOH (10:1) eluent was rechromatographed on silica gel, and a CHCl<sub>3</sub>-EtOAc (5:1) eluent was triturated with benzene to afford 1 (714.7mg). A CHCl<sub>3</sub>-MeOH (1:1) eluent was chromatographed on silica gel, eluting with CHCl<sub>3</sub>, CHCl<sub>3</sub>-Me<sub>2</sub>CO (5:1), (1:1), and Me<sub>2</sub>CO, in that order, to afford eight fractions. Fraction 3 [CHCl<sub>3</sub>-Me<sub>2</sub>CO (5:1) eluent] gave 4 (419.4mg). A MeOH eluent was chromatographed on silica gel, eluting with CHCl<sub>3</sub>-Me<sub>2</sub>CO (5:1) eluent] gave 4 (419.4mg). A MeOH, in that order, to afford fifteen fractions. The mixture of fractions 6-9 were rechromatographed on ODS gel, a MeOH-water (10:1) eluent gave 3 (28.9mg).

*Compound 1 (haploporic acid A).* Colorless powder, mp 203-204°C,  $[\alpha]_D$  +30.0° (*c* 0.1, CHCl<sub>3</sub>).

Compound 2 (haploporic acid B). Colorless oil,  $[\alpha]_D + 37.1^\circ$  (c 0.1, CHCl<sub>3</sub>), FAB(positive)-MS: m/z 871 [M + Na]<sup>+</sup>, m/z 893 [M + 2Na]<sup>+</sup>. IR v<sub>max</sub> (KBr)cm<sup>-1</sup>: 3500-2600, 2930, 1740, 1715, 1640, 1440, 1380, 1220, 1130, 1040, 890, 670. <sup>1</sup>H and <sup>13</sup>C-NMR spectral data are shown in Tables 1 and 2.

Compound 3 (haploporic acid C). Colorless oil,  $[\alpha]_D$  +42.1° (c 0.1, CHCl<sub>3</sub>), FAB(positive)-MS: m/z 825 [M + Na]<sup>+</sup>, m/z 847 [M + 2Na]<sup>+</sup>. IR v<sub>max</sub> (KBr)cm<sup>-1</sup>: 3500-2600, 2930, 1730, 1710, 1640, 1440, 1380, 1220, 1130, 1040, 890. <sup>1</sup>H and <sup>13</sup>C-NMR spectral data are shown in Tables 1 and 2.

*Compound* **4** (*cryptoporic acid E*). Colorless oil,  $[\alpha]_D$  +47.0° (*c* 0.1, CHCl<sub>3</sub>).

Compound 5 prepd. by methanolysis of 1. Compound 1 (180.0mg) was methylated with ethereal CH<sub>2</sub>N<sub>2</sub> (12ml) in usual way to give a colorless solid, which was recrystallized from *n*-hexane-EtOAc (2:1) to afford compound 5 as colorless needles (133.0mg), mp 100-102°C,  $[\alpha]_D$  +18.0° (*c* 0.1, CHCl<sub>3</sub>), FAB(positive)-MS: *m/z* 867 [M + Na]<sup>+</sup>, *m/z* 889 [M + 2Na]<sup>+</sup>. IR v<sub>max</sub> (KBr)cm<sup>-1</sup>:2930, 1740, 1635, 1440, 1380, 1280, 1130, 1000, 890. <sup>1</sup>H and <sup>13</sup>C-NMR spectral data are shown in Tables 1 and 2.

Compound 6 prepd. by reduction and acetylation of 5. To a suspension of LiAlH<sub>4</sub> (100mg) in dry Et<sub>2</sub>O (10ml) was added compound 5 (116.3mg) in dry Et<sub>2</sub>O (7ml) and stirred for 4 hrs at room temp. The reaction mixture was extracted with EtOAc, and the extract (88.6mg) was chromatographed on silica gel. The CHCl<sub>3</sub>-EtOAc (5:1) eluent was acetylated with Ac<sub>2</sub>O-pyridine (each 1ml) to give a colorless oil (compound 6 : 22.9mg),  $[\alpha]_D$  +14.7° (*c* 0.1, CHCl<sub>3</sub>), EIMS: *m/z* 538 [M]<sup>+</sup>, IR v<sub>max</sub> (KBr)cm<sup>-1</sup>:2930, 1740, 1640, 1440, 1380, 1360, 1230, 1100, 1040, 890, 640. <sup>1</sup>H-NMR  $\delta_H$ (CDCl<sub>3</sub>): 4.86(1H, *d*, *J*=1.1Hz), 4.64(1H, *d*, *J*=1.1Hz), 4.29(1H, *dd*, *J*=11.9, 3.9Hz), 4.12(5H, *m*), 3.85(1H, *d*, *J*=10.9Hz), 3.75(1H, *q*, *J*=8.2Hz), 3.63(1H, *d*, *J*=10.9Hz), 3.60(1H, *m*), 3.47(1H, *m*), 2.37(1H, br *d*, *J*=13.5Hz), 2.09, 2.08, 2.06, 2.05(each 3H, *s*), 1.97(1H, *m*), 1.82-1.55(6H, *m*), 1.43-1.17(7H, *m*), 0.82(3H, *s*), 0.75(3H, *s*). <sup>13</sup>C-NMR  $\delta_C$ (CDCl<sub>3</sub>): 171.3, 170.9, 170.8(x 2), 146.6, 107.7, 77.6, 72.8, 67.4, 64.3, 63.6, 62.4, 56.1, 48.9, 38.7, 38.6, 37.3, 36.9, 36.8, 35.7, 27.1, 23.7, 21.0(x 4), 18.4, 17.6, 15.8.

*Methanolysis of compound* **3**. Compound **3** (3.0mg) was methylated with ethereal  $CH_2N_2$  (5ml) to give a colorless crystal (2.9mg), mp 100-103°C,  $[\alpha]_D$  +18.5° (*c* 0.1, CHCl<sub>3</sub>), whose spectral data were identical to those of **5** prepd. from compound **1**.

Preparation of tetraacetate from compound 2. Compound 2 (22.1mg) was methylated with ethereal CH<sub>2</sub>N<sub>2</sub> (5ml), following by reduction with LiAlH<sub>4</sub> (30mg) in Et<sub>2</sub>O (3ml) to afford a residue, which was chromatographed on silica gel. The CHCl<sub>3</sub>-MeOH (5:1) eluent was acetylated with the same reagents as described above to furnish a tetraacetate (9.3mg) as a colorless oil,  $[\alpha]_D$  +14.7° (*c* 0.1, CHCl<sub>3</sub>), of which spectral data were identical to those of **6** prepd. from compound **1**, completely.

Measurement of antibacterial activity. Compounds 1-4 were tested at 200, 100, 50, 25, 12.5, 6.25, 3.12, 1.56, 0.78 and 0.39  $\mu$ g per disc by the paper disc method ( $\phi$ =6mm, thin, TOYO) against Bacillus subtilis NBRC3007, Staphylococcus aureus NBRC3060, Escherichia coli NBRC3301 and Pseudomonas fluorescens NBRC3081. The minimum inhibitory concentrations of compounds 1-4 necessary to cause a clear inhibitory zone over 8 mm are shown in Table 3.

#### 5. Acknowledgement

The authors thank Professor Y. Asakawa and Dr. T. Hashimoto, Tokushima Bunri University for their kind suggestions and discussions.

## 6. References

1) Kobata, K., Wada, T., Hayashi, Y., and Shibata, H., Volemolide, a novel norsterol from the fungus *Lactarius volemus. Biosci. Biotechnol. Biochem.*, **58**, 1542-1544 (1994).

2) Kobata, K., Kano, S., Hayashi, Y., and Shibata, H., New lactarane sesquiterpenoid from the fungus *Russula emetica. Biosci. Biotechnol. Biochem.*, **59**, 316-318 (1995).

3) Wada, T., Kobata, K., Hayashi, Y., and Shibata, H., Two chemotypes of *Boletus cavipes. Biosci. Biotechnol. Biochem.*, **59**, 1036-1039 (1995).

4) Wada, T., Hayashi, Y., and Shibata, H., Asiaticsin A and B, novel prenylated phenolics from *Boletus asiaticus* and *B. paluster* (Boletuceae) fungi. *Biosci. Biotechnol. Biochem.*, **60**, 120-121 (1996).

5) Shibata, H., Fukuda, T., Wada, T., Morita, Y., Hashimoto, T., and Asakawa, Y., Ornatipolide, a novel phenolic metabolite from the basidiomycete *Boletus ornatipes*. *Biosci. Biotechnol. Biochem.*, **56**, 1432-1434 (1998).

6) Shibata, H., Tokunaga, T., Karasawa, D., Hirota, A., Nakayama, M., Nozaki, H., and Tada, T., Isolation and characterization of new bitter diterpenoids from the fungus *Sarcodon scabrosus*. *Agric*. *Biol. Chem.*, **53**, 3373-3375 (1989).

7) Misawa, H., Matsui, Y., Uehara, H., Tanaka, H., Ishihara, M., and Shibata, H., Tyrosinase

7

inhibitors from Albatrellus confluens. Biosci. Biotechnol. Biochem., 56, 1660-1661 (1992).

8) Morita, Y., Hayashi, Y., Sumi, Y., Kodaira, A., and Shibata, H., Haploporic acid A, a novel dimeric drimane sesquiterpenoid from the basidiomycete *Haploporus odorus*. *Biosci. Biotechnol. Biochem.*, **59**, 2008-2009 (1995).

9) Shibata, H., Irie, A., and Morita, Y., New antibacterial diterpenoids from the Sarcodon scabrosus fungus. *Biosci. Biotechnol. Biochem.*, **62**, 2450-2452 (1998).

10) Asakawa, Y., Hashimoto, T., Mizuno, Y., Tori, M., Fukazawa, Y., Cryptoporic acids A-G, drimane-type sesquiterpenoid ethers of isocitric acid from the fungus *Cryptoporus volvatus*, *Phytochem.*, **31**, 579-592 (1992).